NR3C2 and primary aldosteronism: A study by Hayakawa et al. suggested that the quantification of ENaC gamma normalized to CD9 may be a biomarker for mineralocorticoid receptor (MR) activity in primary aldosteronism patients and perhaps other MR-associated diseases [90].